CANbridge Pharmaceuticals Inc. announced that the core part of the ongoing CAN103 Phase 2 trial, in treatment-naïve patients aged 12 or above with Gaucher disease Types I and III, has reached full enrollment.
OSE Immunotherapeutics SA presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, MA.
BerGenBio ASA announced that a poster and an oral presentation summarizing completed studies with its lead product candidate bemcentinib will be presented at the upcoming European Society of Clinical Oncologists Annual Meeting 2023, to be held October 20-24 in Madrid.
Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment Co., Ltd.
Median Technologies announced that the Company will be participating in the prestigious 2023 European Society for Medical Oncology Congress, set to take place in Madrid, Spain.
Everest Medicines announced that its licensing partner, Pfizer Inc. has received approval from the U.S. Food and Drug Administration for VELSIPITY™, an oral, once-daily, selective sphingosine-1-phosphate receptor modulator for adults with moderately to severely active ulcerative colitis.
Verastem Oncology announced the initial safety, pharmacokinetics and recommended Phase 2 dose in the RAMP 203 trial evaluating the safety, tolerability and efficacy of avutometinib in combination with sotorasib in patients with KRAS G12C-mutant non-small cell lung cancer.
Promontory Therapeutics Inc., a clinical stage biotech company advancing immunogenic small molecule approaches in oncology, presented data on its lead therapeutic candidate PT-112, detailing its early molecular effects that culminate in immunogenic cancer cell death.
Leading health and well-being company Humana Inc. announced that, for the third consecutive year and the fourth time overall, its statewide Humana HMO Medicare Advantage plan in Tennessee has achieved the highest possible 5-star rating from the Centers for Medicare & Medicaid Services.
Humana Tennessee Medicare Advantage HMO Plan Achieves Highest Quality Rating for 2024 Read More »
Immunic, Inc. announced the presentation of data from the company’s phase 1b clinical trial of IMU-856, an orally available and systemically acting small molecule modulator that targets SIRT6, in patients with celiac disease in a moderated poster session at the United European Gastroenterology Week 2023, taking place October 14-17 in Copenhagen.
